CryoStor® CS10

cGMP-manufactured, animal component-free, defined cryopreservation medium with 10% DMSO

CryoStor® CS10

cGMP-manufactured, animal component-free, defined cryopreservation medium with 10% DMSO

From: 425 USD
Catalog #
(Select a product)
cGMP-manufactured, animal component-free, defined cryopreservation medium with 10% DMSO
Add to Wish List

Product Advantages


  • cGMP-manufactured with USP grade/highest-quality components
  • Ready-to-use

  • Serum-free and protein-free

  • Animal component-free

  • FDA master file

  • Sterility, endotoxin, and cell-based quality control testing

Overview

Maximize post-thaw cell recovery and viability following cryopreservation at very low temperatures (-70°C to -196°C) with ready-to-use CryoStor® CS10 medium from BioLife Solutions. Serum-free, animal component-free, and cGMP-manufactured, this defined medium provides a safe, protective environment that is recommended for the cryopreservation of a variety of sensitive cell and sample types, including myeloma cell lines, human pluripotent stem cells, blood-derived cells, and more. Available in a variety of convenient formats, CryoStor® CS10 is formulated with USP-grade components to minimize variability and contains 10% DMSO.
Contains
• 10% dimethyl sulfoxide (DMSO)
• Other ingredients
Cell Type
B Cells, CHO Cells, Hematopoietic Stem and Progenitor Cells, Hybridomas, Intestinal Cells, Macrophages, Mesenchymal Stem and Progenitor Cells, Monocytes, Myeloma, NK Cells, Other, Pluripotent Stem Cells, T Cells
Species
Human, Mouse, Non-Human Primate, Other, Rat
Application
Cryopreservation
Brand
CryoStor
Area of Interest
Cord Blood Banking, Epithelial Cell Biology, Immunology, Stem Cell Biology
Formulation Category
Animal Component-Free, Serum-Free

Data Figures

Figure 1. Immune Cells Cryopreserved in CryoStor®CS10 Show Reproducibly High Post-Thaw Cell Viability

CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as measured by Propidium Iodide staining (ranging from 94.3 - 97.9%).

Figure 2. Immune Cells Cryopreserved in CryoStor®CS10 Retain Functionality Post-Thaw

(A) Human peripheral blood Pan-T cells cryopreserved in CryoStor®CS10 were thawed and cultured with or without the addition of T cell activating factors. Cells from Donors 1-3 were cultured in RPMI Medium supplemented with 10% FBS, with (activated) or without (control) 40 ng/mL PMA and 1 ug/mL Ionomycin for 24 hours. Cells from Donors 4-5 were cultured in ImmunoCult™-XF T Cell Expansion Medium (Catalog #10981), with (activated) or without (control) ImmunoCult™ Human CD3/CD28 T Cell Activator (Catalog #10971) for 48 hours. Supernatants were collected from the cultures, and concentrations of secreted cytokines were determined using the Human IL-2 ELISA Kit (Catalog #02006). Activation by either PMA and Ionomycin or ImmunoCult™ Human CD3/CD28 T Cell Activator led to increased secretion of IL-2 compared to unstimulated control cultures. (B) Human B cells (Donors 6 - 11) cryopreserved in CryoStor®CS10 were thawed and activated with 1 µg/mL CD40 and 100 ng/mL IL-21 for 7 days. Supernatants were collected from the cultures and immunoglobulin G (IgG) production was measured using the Human IgG ELISA Antibody Pair Kit (Catalog #01994). Compared to unstimulated control cultures, B cell activation led to increased IgG​ ​secretion.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
CryoStor® CS10
Catalog #
07959, 07931, 07955, 07940, 07952
Lot #
For Catalog 07959, 07931, 07955, 07940, 07930, and 07952: All lots. For Catalog 100-1061: 24167 or higher
Language
English
Document Type
Safety Data Sheet
Product Name
CryoStor® CS10
Catalog #
07959, 07931, 07955, 07940
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area
Workflow Stages
Workflow Stages for

Resources and Publications

Educational Materials (24)

Publications (119)

An integrated patient-derived colon organoids platform as a functional model for nutraceutical and stress response. A. Costantino et al. iScience 2026 Jun

Abstract

Nutraceuticals are increasingly investigated for their capacity to modulate oxidative and inflammatory stress, yet preclinical testing still relies largely on immortalized cell lines or animal models that poorly recapitulate human epithelial complexity. To address this gap, we developed an integrated platform based on patient-derived colon organoids generated from non-tumoral mucosa and maintained under proliferative or differentiation conditions to model distinct epithelial states. The system combines millifluidic measurement of individual organoid mass, density, and diameter with bulk RNA sequencing and digital PCR profiling to enable multiparametric characterization. Transcriptional analysis revealed state-specific gene programs and shifts in epithelial and immune-related pathways, while biophysical measurements captured structural remodeling. In this pilot validation, a defined oxidative insult followed by nutraceutical treatment elicited coordinated transcriptional and phenotypic responses. This integrated approach provides a scalable and physiologically relevant framework for functional nutraceutical profiling and mechanistic studies of epithelial stress responses.
Microglial clonal dynamics and the impact of clonal hematopoiesis in autologously transplanted rhesus macaques. Y. Zhou et al. Cell reports 2026 Jul

Abstract

Microglia are central nervous system (CNS)-resident macrophages, with key roles in immune surveillance, phagocytosis, and synaptic pruning. Yolk sac-derived microglia show minimal turnover from hematopoietic stem/progenitor cells (HSPCs) under steady-state conditions in mice. However, clinical benefits observed in patients receiving HSPC gene therapies for CNS disorders suggest functional integration of HSPC-derived cells. To investigate microglia replacement and the impact of clonal hematopoiesis (CH) on microglia, we analyzed microglia in rhesus macaques receiving barcoded or CRISPR-edited (TET2-mutant) HSPC transplants. We found that <2% microglia were derived from HSPCs many years following transplant, with no evidence of enhanced replacement in CH. The rare HSPC-derived tissue-resident cells exhibited a macrophage-like gene expression profile. Our results demonstrate limited long-term microglia replacement from adult HSPCs, even with CH, contrasting prior human studies. This work provides insights into microglia ontogeny and informs strategies for CNS-targeted HSPC gene therapies and interpretation of CH-related neuroprotection.
Profiling miRNAs Involved in Human Oligodendrocyte Precursor Cell Differentiation and Maturation. M. Barzegar et al. Cells 2026 Jul

Abstract

MicroRNAs (miRNAs) are conserved post-transcriptional regulators that play essential roles in cellular development and differentiation. Although miRNAs involved in oligodendrocyte lineage cell (OLLC) differentiation have been extensively studied in rodent models, their functions in human oligodendrocyte (OL) development remain poorly understood. To address this, we used a human embryonic stem cell (hESC) reporter system and an optimized differentiation protocol to generate and isolate well-characterized OLLCs at defined developmental stages. Next-generation sequencing-based miRNA profiling identified stage-specific miRNAs associated with OL lineage specification and maturation. In addition to canonical OL-associated miRNAs, we identified several previously uncharacterized oligodendrocyte progenitor cell (OPC)/oligodendrocyte (OL)-enriched miRNAs, including miR-3943, miR-4286, miR-1296-5p, miR-488-3p, miR-675-5p, and miR-128-3p, as potential novel regulators and molecular markers for human OLLC development. Computational target analysis further identified candidate regulatory genes, including ZNF488, DLX1, CSNK2B, and KCNJ1, and predicted their association with AKT, SMAD2/3, estrogen-receptor, and insulin-signaling pathways. Together, these findings provide a comprehensive stage-specific miRNA resource for human OL lineage development and provide insight into potential miRNA-mediated regulatory networks governing human OL development.